We are live on ! Find out more
BC

Broadwood Capital Portfolio holdings

AUM $1.42B
1-Year Est. Return 34.72%
This Fund
S&P 500
This Quarter Est. Return
-5.04%
1 Year Est. Return
+34.72%
3 Year Est. Return
+45.97%
5 Year Est. Return
+44.27%
10 Year Est. Return
+866.96%
AUM
$1.34B
AUM Growth
-$83.7M
Cap. Flow
+$6.76M
Cap. Flow %
0.51%
Top 10 Hldgs %
100%
Holding
7
New
Increased
1
Reduced
Closed

Top Buys

Rank Stock Value
1
IMDX
Insight Molecular Diagnostics
IMDX
+$6.76M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Consumer Staples 39.99%
2 Healthcare 39.26%
3 Industrials 11.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MNST icon
1
Monster Beverage
MNST
$94.3B
$535M 39.99%
9,312,976
STAA icon
2
STAAR Surgical
STAA
$1.21B
$462M 34.52%
8,783,082
AXON
3
Axon Enterprise
AXON
$42.5B
$148M 11.09%
760,062
IWM icon
4
iShares Russell 2000 ETF
IWM
$79.8B
$129M 9.66%
690,000
LCTX icon
5
Lineage Cell Therapeutics
LCTX
$269M
$49.3M 3.68%
34,935,485
IMDX
6
Insight Molecular Diagnostics
IMDX
$150M
$11.5M 0.86%
2,509,067
+1,341,382
+115% +$6.76M
SER icon
7
Serina Therapeutics
SER
$30M
$2.68M 0.2%
85,219

Similar funds

Broadwood Capital's Q2 2023 Portfolio in Review

As of Q2 2023, Broadwood Capital held 7 positions worth $1.34B, down 5.9% from $1.42B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q2 2023: portfolio turnover was 0%. Broadwood Capital opened no new positions and made no exits, leaving the 7-position portfolio largely intact.

By sector, the portfolio is most concentrated in Consumer Staples at 40% of assets, up from 35% a quarter earlier, followed by Healthcare and Industrials.

  • Broadwood Capital added most to Insight Molecular Diagnostics in Q2 2023, an estimated $6.76M increase.
  • Broadwood Capital's ten largest holdings make up 100% of its $1.34B portfolio in Q2 2023.
  • Broadwood Capital opened 0 new positions and closed 0 in Q2 2023.
  • Broadwood Capital's portfolio value fell 5.9% quarter-over-quarter to $1.34B.

Based on Broadwood Capital's 13F filing for Q2 2023, filed 14 Aug 2023.